Press Announcing a ground breaking collaboration of Lipidnanoparticles industry experts...
Contract Pharma | Pharma Matters Q&A interview with our CEO, Jarlath Keating
A conversation with Jarlath Keating, CEO of Phosphorex, on the future of LNPs in pharmaceutical innovation.
In recent years, lipid nanoparticles (LNPs) have emerged as a groundbreaking technology in the pharmaceutical world, revolutionizing the delivery of complex therapeutic molecules like RNA and DNA.
Press Announcement: Phosphorex and NOF Corporation launches Innovation and Training Center in Hopkington, MA....
Phosphorex, an Ampersand Capital Partners company, and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today the appointment of David Tammaro as Chief Financial Officer.
Following the recent growth capital investment from Ampersand Capital Partners, Phosphorex announced today the appointment of Jarlath Keating as Chief Executive Officer.
Phosphorex, a drug delivery-focused contract development and manufacturing organization providing microspheres and polymer and lipid nanoparticles, today announced a majority recapitalization by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the health
ONdrugDelivery article to discuss how automation of Lipid Nanoparticles production can benefit the development and manufacture of RNA-based drugs and vaccines.
Phosphorex & Dolomite experts share their insights about the most important considerations when making liposomes and lipid nanoparticles (LNPs) with microfluidics.
Phosphorex Presents Its Nanosuspension Formulation at Controlled Release Society Annual Meeting
Phosphorex announced today the acquisition of new laboratory and office space in Hopkinton, MA to meet the increasing demand for its products and services.
AstraZeneca Highlights Collaboration with Phosphorex on use of Zetafinity® Technology to More Effectively Target Immune Cells